Search Results - "Kishan, A U"

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT) by Wolfe, Sydney, Diven, Marshall A, Marciscano, Ariel E, Zhou, Xi Kathy, Kishan, A. U, Steinberg, M. L, Miccio, Joseph A, Camilleri, Philip, Nagar, Himanshu

“…Background Ultra-hypofractionated regimens for definitive prostate cancer (PCa) radiotherapy are increasingly utilized due in part to promising safety and…”
Get full text

Absolute Percentage of Pattern 4 Disease as a Prognostic Measure for Intermediate-risk Prostate Cancer Treated with Stereotactic Body Radiotherapy by Glicksman, R.M., Kishan, A.U., Quon, H., Shabsovich, D., Juarez, J., Jiang, T., Steinberg, M.L., Zhang, L., Loblaw, A.

“…Intermediate-risk prostate cancer is heterogenous. The absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) is a possible…”
Get full text

Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis by Subiela, J D, Gomis Sellés, E, Maldonado, A, Lopez Campos, F, Aumatell Ovide, J, Ajuria Illarramendi, O, González-Padilla, D A, Gajate, P, Ortega Polledo, L E, Alonso Y Gregorio, S, Guerrero-Ramos, F, Gómez Dos Santos, V, Rodríguez-Patrón, R, Calais, J, Kishan, A U, Burgos Revilla, F J, Couñago, F

“…After primary radiotherapy, biochemical recurrence is defined according to the Phoenix criteria as a prostate-specific antigen (PSA) value >2 ng/ml relative to…”
Get full text

Four-year Prostate-specific Antigen Response Rate as a Predictive Measure in Intermediate-risk Prostate Cancer Treated With Ablative Therapies: The SPRAT Analysis by Glicksman, R.M., Kishan, A.U., Katz, A.J., Mantz, C.A., Collins, S.P., Fuller, D.B., Steinberg, M.L., Shabsovich, D., Zhang, L., Loblaw, A.

“…There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy…”
Get full text

Branched projections in the auditory thalamocortical and corticocortical systems by Kishan, A.U, Lee, C.C, Winer, J.A

“…Abstract Branched axons (BAs) projecting to different areas of the brain can create multiple feature-specific maps or synchronize processing in remote targets…”
Get full text

Interfractional Geometric Variations and Dosimetric Benefits of Online Adaptive Stereotactic Body Radiotherapy of Prostate Bed After Radical Prostatectomy by Cao, M., Gao, Y., Yoon, S., Yang, Y., Sheng, K., Sachdeva, A., Ballas, L.K., Steinberg, M.L., Kishan, A.U.

“…To evaluate volumetric and shape variations of target and organs-at-risk (OAR) of prostate patients receiving stereotactic body radiotherapy (SBRT) after…”
Get full text

4-Year PSA Response Rate as a Predictive Measure in Intermediate Risk Prostate Cancer Treated With Ablative Therapies: The Sprat Analysis by Glicksman, R., Kishan, A.U., Katz, A.J., Mantz, C.A., Collins, S.P., Fuller, D.B., Steinberg, M.L., Shabsovich, D., Zhang, L., Loblaw, D.A.

“…There is a lack of early predictive measures of outcome for patients with intermediate-risk prostate cancer (PCa) treated with stereotactic body radiotherapy…”
Get full text

Telemedicine Perspectives in Radiation Oncology by Parikh, N.R., Philipson, R., van Dams, R., Chang, E.M., Hegde, J.V., Kishan, A.U., Kaprealian, T.B., Steinberg, M.L., Raldow, A.

“…Given the changes to Radiation Oncology clinic workflow inspired by the COVID-19 pandemic, this study sought to determine the attitudes and perceptions of…”
Get full text

Multivariate Model for Predicting Overall Survival in Malignant Pleural Mesothelioma After Adjuvant Radiotherapy by Li, V.R., Wang, Z., Yu, V.Y., Dams, R.V., Philipson, R., Lee, P., Kishan, A.U., Lee, A., Qi, X.

“…Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer arising from the cells of the thoracic pleura. Its anatomic complexity, large surface…”
Get full text

Patient-Reported Quality of Life Outcomes After Integrating Exclusive Liquid Meal Replacement in Patients With Head and Neck Cancer Undergoing Chemoradiation: Results From a Phase II Study by Valle, L., Chu, F.I., Erman, A., Hernandez, J., Koah, E., Raldow, A., Wong, D.J., Steinberg, M.L., Kishan, A.U., Chin, R.K., Hegde, J.V.

“…Preventing malnutrition during chemoradiation (CRT) for head and neck cancer (HNC) is crucial for treatment adherence, minimizing treatment-related…”
Get full text

Prostate-Centric vs. Bony-Centric Registration in the Definitive Treatment of Node-Positive Prostate Cancer With Simultaneous Integrated Boost: A Dosimetric Comparison by Wu, T.C., Xiang, M., Nickols, N.G., Tenn, S.E., Agazaryan, N., Hegde, J.V., Steinberg, M.L., Cao, M., Kishan, A.U.

“…To determine the impact of daily shifts based on rigid registration to intraprostatic markers (IPMs) on coverage of boost doses delivered to gross nodal…”
Get full text

Patterns of Failure in Men With Radiorecurrent Prostate Cancer: A Post-Hoc Analysis of Two Prospective Ga-68-PSMA PET/CT Imaging Trials by Smith, C.P., Xiang, M., Armstrong, W.R., Nickols, N.G., Steinberg, M.L., Reiter, R.E., Rettig, M., Czernin, J., Calais, J., Kishan, A.U.

“…The advent of novel nuclear medicine imaging modalities, such as prostate specific membrane antigen positron emission tomography/computed tomography (PSMA…”
Get full text

Prognostic and Predictive Performance of Routine Clinicopathologic Variables in 10,535 Men Enrolled on Randomized Phase III Trials in Localized Prostate Cancer by Dess, R.T., Sun, Y., Bolla, M., Zapatero, A., Malone, S., Kishan, A.U., Roy, S., Jackson, W.C., Lawton, C.A.F., Sartor, O., Nguyen, P.L., Michalski, J.M., Pisansky, T.M., Roach, M., Sandler, H.M., Schipper, M., Feng, F.Y., Spratt, D.E.

“…Standard clinicopathologic variables including T-category, Gleason grade, and prostate-specific antigen (PSA) guide the management of localized prostate…”
Get full text

Patterns of Utilization and Clinical Adoption of 0.35 MR-Guided Radiation Therapy in the United States — Understanding the Transition to Adaptive, Ultra-Hypofractionated Treatments by Chuong, M.D., Clark, M.A., Henke, L.E., Kishan, A.U., Portelance, L., Parikh, P.J., Nagar, H., Rosenberg, S.A., Mehta, M.P., Abdelrhman, T.R., Smith, A.J.T., Seung, S.K., Zaki, B., Mak, R.H.

“…Magnetic resonance imaging-guided radiation therapy (MRgRT) utilization is rapidly expanding worldwide, driven by advanced capabilities including continuous…”
Get full text

Clinical Outcomes of Single-Isocenter Versus Multiple-Isocenter Stereotactic Radiosurgery Techniques for Multiple Brain Metastases by Deng, J., Li, M.K., Savjani, R.R., Chu, F.I., Tenn, S.E., Lee, C., Agazaryan, N., Yang, I., Everson, R., Kim, W., Pouratian, N., Kishan, A.U., Chin, R.K., Steinberg, M.L., Kaprealian, T.B., Hegde, J.V.

“…There are multiple technical approaches for stereotactic radiosurgery (SRS) delivery to multiple brain metastases, including single-isocenter (SIT) and…”
Get full text

Pan-Cancer Analysis of Prognostic Metastatic Phenotypes by Zaorsky, N.G., Wang, X., Lehrer, E.J., Lin, C., Garrett, S.M., Zhang, Y., DeGraff, D., Spratt, D.E., Trifiletti, D.M., Kishan, A.U., Showalter, T.N., Park, H.S.M., Yang, J.T., Wang, M.

“…Staging for metastatic disease is unreliable; there is usually only one category of Stage IV in the American Joint Commission on Cancer (AJCC) 8th edition, but…”
Get full text

Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics by Sutera, P., Van der Eecken, K., Kishan, A.U., Hamid, A., Grist, E., Attard, G., Lotan, T.L., Mendes, A., Sweeney, C., Paller, C., Carducci, M., Ross, A.E., Pienta, K., Feng, F.Y., Eisenberger, M., Antonarakis, E.S., Ost, P., Tran, P.T., Deek, M.P.

“…Recent evidence has suggested metastatic cancer represents a disease spectrum rather than a binary state and metastasis-directed therapy (MDT) such as…”
Get full text

Prognostic Significance of the Risk of Non-localized Disease on PSMA/PET: Comparative Performance of a Novel, PSMA/PET-Derived Risk Stratification Tool for High-Risk Prostate Cancer in a Large, Multi-Institutional Cohort by Ma, T.M., Xiang, M., Tilki, D., Karnes, R.J., Stish, B.J., Martinez-Monge, R., Tendulkar, R.D., Klein, E.A., Tran, P.T., Tosoian, J., Berlin, A., Tward, J.D., Merrick, G.S., Spratt, D.E., Krauss, D.J., Horwitz, E.M., Gafita, A., Grogan, T., Calais, J., Kishan, A.U.

“…Occult non-localized disease (N1 or M1) at the time of definitive treatment of high-risk prostate cancer (HR-PCa) underlies most treatment failures. We…”
Get full text

Working Towards a New Definition of Biochemical Failure in the Era of Stereotactic Body Radiation Therapy for Prostate Cancer by Ma, T.M., Roy, S., Mantz, C.A., Fuller, D.B., Miszczyk, L., Napieralska, A., Namysł-Kaletka, A.J., Bagshaw, H.P., Buyyounouski, M.K., Glicksman, R., Loblaw, D.A., Katz, A.J., Nickols, N.G., Steinberg, M.L., Philipson, R., Aghdam, N., Suy, S., Pepin, A., Collins, S.P., Kishan, A.U.

“…Since the seminal Phoenix definition (nadir PSA+2) of biochemical failure (BCF) was published in 2006, increasingly more patients with low- and…”
Get full text

Patterns and Predictors of Distant Failure After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Retrospective Multi-Institutional Analysis by Shabsovich, D., Xiang, M., Katz, A.W., Mantz, C.A., Fuller, D.B., van Dams, R., Philipson, R., Juarez, J.E., Ma, T.M., Pepin, A., Suy, S., Stephans, K.L., Murthy, V., Nickols, N.G., Miszczyk, L., Aghdam, N., Glicksman, R., Collins, S.P., Loblaw, D.A., Kishan, A.U.

“…Stereotactic body radiation therapy (SBRT) has emerged as a promising modality for the treatment of prostate cancer (PCa) and involves the delivery of ablative…”
Get full text